首页关于道一研发平台优势产品在研管线商业模式合作洽谈
UNIBEST 参股公司
深圳奥祺深圳高壁垒药物引进 · 复杂制剂 · License-in/out上海道一臻合上海CGT 疗法靶向递送技术平台上海优合贝德上海敬请期待Unibest 主体 · 医药外贸与全球注册
上海博瑞康上海敬请期待参股企业
浙江汰泽浙江绿色制药 · 连续流合成 · 智能制剂病毒载体解决了「递得进」，LNP 解决了「造得出」。下一代核酸疗法的胜负手在「递得准、递得安全」。道一生物以自研可电离脂质与配体库为底座，为肝、脾、肺等非肝组织提供一体化靶向递送设计。
mRNA 疫苗完成了核酸药物的产业化验证。基因编辑、体内细胞治疗、蛋白替代疗法正在把核酸药物推向更广阔的治疗场景 —— 而每一种新场景，都对递送的「组织选择性」与「安全性」提出更高要求。
mRNA vaccines industrialised nucleic acid drugs. Gene editing, in vivo cell therapy and protein replacement are now pushing them into far broader indications — and every new indication raises the bar on tissue selectivity and safety of delivery.
遗传病、肿瘤及代谢性疾病
Genetic, oncology & metabolic disease
致病基因修复、沉默或调控
Repair, silence or modulate the disease-causing gene
肿瘤、自身免疫病、再生医学
Oncology, autoimmune disease, regenerative medicine
改造免疫细胞或干细胞，增强靶向杀伤或修复功能
Engineer immune or stem cells for targeted killing or repair
罕见病、慢性病
Rare and chronic disease
补充缺失或缺陷蛋白
Restore missing or defective proteins
传染病预防
Infectious disease prevention
表达抗原并诱导特异性免疫应答
Express antigen and induce specific immune response
('AAV / LV 载体转导高效、表达持久，是基因编辑的成熟路线，但存在免疫原性、大剂量给药的安全隐患与规模化生产瓶颈。行业迫切需要「非病毒、可重复给药」的递送方案。', 'AAV and lentiviral vectors transduce efficiently and express durably, but carry immunogenicity, dose-related safety concerns and manufacturing bottlenecks. The field needs a non-viral route that can be re-dosed.')
AAV and lentiviral vectors transduce efficiently and express durably, but carry immunogenicity, dose-related safety concerns and manufacturing bottlenecks. The field needs a non-viral route that can be re-dosed.
('目前成熟的 LNP 应用集中在静脉肝靶向与肌注疫苗。脾、肺、背根神经节等组织与特定细胞类型的靶向递送，仍是限制核酸疗法边界的关键瓶颈 —— 这正是道一的切入点。', "Today's mature LNP applications are intravenous liver targeting and intramuscular vaccines. Spleen, lung, dorsal root ganglion and defined cell types remain the bottleneck that limits how far nucleic acid therapy can reach — this is exactly where Harmony Tao works.")
Today's mature LNP applications are intravenous liver targeting and intramuscular vaccines. Spleen, lung, dorsal root ganglion and defined cell types remain the bottleneck that limits how far nucleic acid therapy can reach — this is exactly where Harmony Tao works.
同一个脂质材料平台，三种给药路径，解决三类临床未满足需求。
One lipid platform, three administration routes, three unmet clinical needs.
脂质分子库 + 配体结构库 + Lipoeasy® 验证工具 + T-LNP 体内外数据库，四个真实资产沉淀成一个可复用的递送设计引擎，并用 AI 体内 / 体外预测模型把「配方筛选」从试错变成预测。
基因编辑疗法
Gene editing
体内细胞治疗
In vivo cell therapy
('一体化递送设计服务：脂质材料定制 · LNP 处方筛选 · 理化表征 · 体内外转染验证 · 动物药效评价。', 'End-to-end delivery design: custom lipid synthesis, LNP formulation screening, physicochemical characterisation, in vitro / in vivo transfection and animal efficacy evaluation.')
End-to-end delivery design: custom lipid synthesis, LNP formulation screening, physicochemical characterisation, in vitro / in vivo transfection and animal efficacy evaluation.